Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study Academic Article Article uri icon

Overview

MeSH Major

  • Carcinoma, Squamous Cell
  • Vulvar Neoplasms
  • cdc25 Phosphatases

abstract

  • Stemcentrx Inc.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(16)30565-4

PubMed ID

  • 27932068

Additional Document Info

start page

  • 42

end page

  • 51

volume

  • 18

number

  • 1